Reported 6 months ago
Viking Therapeutics' stock has seen a significant rise in 2024 due to its experimental weight loss therapy, VK2735, garnering investor interest. Despite a recent dip in stock value following trial updates for another drug, VK2809, analysts still see potential in VK2735, estimating it as a potential $21 billion yearly therapy. While the short-term market volatility and uncertainty persist, patient investors may find Viking Therapeutics to be a promising investment with its innovative assets, focusing on weight loss treatments and potential for partnerships or buyouts.
Source: YAHOO